AstraZeneca AB v Medis Pharma Pty Ltd

In the case of AstraZeneca AB v Medis Pharma Pty Ltd, the Federal Court was tasked with determining an application to extend the confidentiality regime between the parties to include certain in-house legal advisers of the applicant. The dispute between the parties centred around the interpretation and application of the confidentiality regime that had been established by a previous court order. The applicants sought to extend the scope of this regime to ensure that specific legal advisers could also handle confidential information under certain conditions.

The primary legal issue the court had to address was whether the confidentiality regime should be extended to include the named in-house legal advisers. In assessing this, the court considered several factors, including the necessity of including these advisers in the confidentiality regime to enable them to give instructions on behalf of the applicant and the balance between the risk of inadvertent or accidental disclosure and the need for the applicants to seek appropriate advice and provide informed instructions.

The court found that the balance tipped in favour of extending the confidentiality regime to the specified advisers, provided they signed a confidentiality undertaking. The undertakings would ensure that these individuals were bound by the same obligations as the existing parties to the confidentiality regime. The court allowed the application in part, making orders to extend the confidentiality regime to include the named advisers on the condition that they sign the required undertakings. The orders also mandated that a copy of these undertakings be provided to the respondent's solicitors.

These orders were made to ensure that the confidentiality regime was sufficiently robust to protect the sensitive information involved in the litigation while allowing the applicants to manage their legal affairs effectively. The court’s decision was carefully balanced to meet the needs of the applicants without compromising the integrity of the confidential information.